[go: up one dir, main page]

AU5298699A - Dnazymes and methods for treating hpv-related disorders - Google Patents

Dnazymes and methods for treating hpv-related disorders

Info

Publication number
AU5298699A
AU5298699A AU52986/99A AU5298699A AU5298699A AU 5298699 A AU5298699 A AU 5298699A AU 52986/99 A AU52986/99 A AU 52986/99A AU 5298699 A AU5298699 A AU 5298699A AU 5298699 A AU5298699 A AU 5298699A
Authority
AU
Australia
Prior art keywords
dnazymes
methods
related disorders
treating hpv
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52986/99A
Inventor
Murray J. Cairns
Lun-Quan Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Research Pty Ltd
Original Assignee
Johnson and Johnson Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Research Pty Ltd filed Critical Johnson and Johnson Research Pty Ltd
Publication of AU5298699A publication Critical patent/AU5298699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU52986/99A 1998-08-13 1999-08-11 Dnazymes and methods for treating hpv-related disorders Abandoned AU5298699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9637398P 1998-08-13 1998-08-13
US60096373 1998-08-13
PCT/IB1999/001486 WO2000009673A1 (en) 1998-08-13 1999-08-11 Dnazymes and methods for treating hpv-related disorders

Publications (1)

Publication Number Publication Date
AU5298699A true AU5298699A (en) 2000-03-06

Family

ID=22257065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52986/99A Abandoned AU5298699A (en) 1998-08-13 1999-08-11 Dnazymes and methods for treating hpv-related disorders

Country Status (2)

Country Link
AU (1) AU5298699A (en)
WO (1) WO2000009673A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2365901A1 (en) 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AUPQ201499A0 (en) * 1999-08-04 1999-08-26 Unisearch Limited Treatment of inflammatory and malignant diseases
JP2004525602A (en) * 2000-04-13 2004-08-26 メディカル ユニバーシティー オブ サウス カロライナ Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of using them
EP1702983A3 (en) 2000-04-13 2007-01-10 Medical University of South Carolina Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
US7704965B2 (en) 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
WO2005017127A2 (en) * 2003-02-21 2005-02-24 The Penn State Research Foundation Rna interference compositions and methods
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
DE102010007562A1 (en) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatological, pharmaceutical composition suitable for oligonucleotides
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CN103013953B (en) * 2012-10-19 2014-09-17 中国科学院成都生物研究所 DNA enzyme for shearing DNA
US10117947B2 (en) 2013-09-18 2018-11-06 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
CN103525819B (en) * 2013-10-22 2015-09-02 上海市农业科学院 A kind of for suppressing the DNAzyme of PRRSV infection
KR20180095511A (en) 2015-10-30 2018-08-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Targeted Cancer Therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
BRPI9809433B1 (en) * 1997-04-29 2015-09-08 Scripps Research Inst enzymatic DNA molecules
US6361941B1 (en) * 1998-03-27 2002-03-26 Johnson & Johnson Research Pty Limited Catalytic nucleic acid-based diagnostic methods

Also Published As

Publication number Publication date
WO2000009673A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
AU7538398A (en) Emulsion for well and formation treatment
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
AU1332101A (en) Systems and methods for treating spinal pain
AU7264298A (en) Apparatus and method for the reduction of snoring
AU7383398A (en) Therapeutic glasses and method for using the same
AU8769098A (en) System for treating patients with anxiety disorders
AU2373200A (en) Apparatuses and methods for forming assemblies
AU5439996A (en) Compositions and methods for treating pain
AU6262998A (en) Method and apparatus for treating airway disorders
AU2676397A (en) Methods for treating middle and inner ear disorders
AU3299197A (en) Method and device for treating muscular ailments
AU1833699A (en) Device and method for treating parkinson's disease
AU3891299A (en) Combination therapy for treatment of depression
AU2327599A (en) Compositions and methods for treating autoimmune diseases
AU7823098A (en) Methods for treating obesity
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
AU5838700A (en) Method for treating and preventing finger disorders
AU2058697A (en) Treatment of sleep disorders
AU2469599A (en) Methods for the prevention and treatment of fibrosis and sclerosis
AU5042000A (en) Methods of treating proliferative disorders
AU3488699A (en) Surface treatment process and system
AU6151899A (en) Methods of treating chronic pain
AU1556497A (en) Agents for the treatment and prevention of aids
AU5610198A (en) Compounds and methods for treating and preventing bacterial and viral disease
AU6242498A (en) Methods for treating central and peripheral nerve pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 14, NO 21, PAGE(S) 3916-3919 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 52986/99

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase